SeaCrest Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

SeaCrest Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-300	Closed	-$44K	–	656
2022 Q2	$44K	Buy	+300	New	+$42.6K	0.01%	1170
2019 Q2	–	Sell	-400	Closed	-$37K	–	567
2019 Q1	$37K	Hold	400	–	–	0.01%	1046
2018 Q4	$29K	Hold	400	–	–	0.01%	1087
2018 Q3	$35K	Buy	400 +100	+33%	+$10.1K	0.01%	1141
2018 Q2	$30K	Sell	300 -100	-25%	-$9.92K	0.01%	1186
2018 Q1	$48K	Hold	400	–	–	0.01%	964
2017 Q4	$51K	Buy	+400	New	+$50.3K	0.01%	948

Other funds holding ALNY

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SeaCrest Wealth Management's ALNY Position: Q3 2022 in Review

SeaCrest Wealth Management sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2022, closing a stake of 300 shares — an estimated $44K sold.

SeaCrest Wealth Management first reported a position in ALNY in Q4 2017 and held it in 7 quarters. The position peaked at $51K in Q4 2017. 497 funds tracked by Wall St. Rank hold ALNY as of Q3 2022.

SeaCrest Wealth Management reported no remaining Alnylam Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
SeaCrest Wealth Management sold 300 Alnylam Pharmaceuticals shares in Q3 2022, an estimated $44K.
SeaCrest Wealth Management first reported a position in Alnylam Pharmaceuticals in Q4 2017 and held it in 7 quarters.
SeaCrest Wealth Management's Alnylam Pharmaceuticals position peaked at $51K in Q4 2017.
497 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2022.

Based on SeaCrest Wealth Management's 13F filing for Q3 2022, filed 15 Nov 2022.